Retatrutide vs tirzepatide: how much more weight loss?

Retatrutide and tirzepatide are both injectable obesity drugs from Eli Lilly, but they are not the same kind of drug. Tirzepatide is already approved and on pharmacy shelves as Zepbound and Mounjaro. Retatrutide is still in testing and adds a third hormone target that tirzepatide does not have. The early numbers suggest retatrutide takes off more weight, and this article walks through exactly how much more, how strong the evidence really is, and where it is still thin.

The short version of the science

Both drugs work by copying gut and pancreas hormones that control hunger, fullness, and blood sugar. They slow down how fast your stomach empties, they tell your brain you are full sooner, and they cut the background "food noise" that keeps people reaching for snacks. The difference is how many hormone systems each drug touches.

Tirzepatide is a dual agonist. It activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both of these mostly work on the appetite and blood-sugar side of metabolism.

Retatrutide is a triple agonist. It hits those same two receptors plus a third one: the glucagon receptor (GCGR). That third target is the whole story here. Glucagon does something the other two hormones do not. It can raise your resting metabolic rate, push your liver to burn its own fat, and increase the calories you spend at rest. So instead of only turning down how much you eat, retatrutide may also turn up how much you burn.

That extra mechanism is the reason researchers and investors got excited. But "more mechanisms" is not the same as "more proven." Tirzepatide has years of large Phase 3 trials behind it. Retatrutide, as of mid-2026, has strong Phase 2 data and one large Phase 3 readout that has not yet been published in full. Keep that gap in mind as we go.

How the two drugs differ at a glance

Feature	Retatrutide	Tirzepatide
Maker	Eli Lilly	Eli Lilly
Hormone targets	GLP-1 + GIP + glucagon (triple)	GLP-1 + GIP (dual)
Approval status (mid-2026)	Investigational, not FDA approved	FDA approved (Zepbound for weight, Mounjaro for diabetes)
Dosing	Once-weekly injection	Once-weekly injection
Top doses studied	4, 8, 9, 12 mg	5, 10, 15 mg
Extra mechanism	Glucagon raises energy burn and liver fat oxidation	None beyond the two incretins
Strongest evidence	Phase 2 (published) + Phase 3 topline (not yet published in full)	Multiple completed, published Phase 3 trials

This table is the honest summary. Retatrutide may win on the headline weight-loss number, but tirzepatide wins on the depth and maturity of its evidence. Both facts are true at the same time.

What the actual evidence shows

Retatrutide: the Phase 2 trial

The most important published study on retatrutide is a Phase 2 trial run by Ania Jastreboff and colleagues, published in The New England Journal of Medicine in 2023. It enrolled 338 adults with obesity, or overweight plus a weight-related health problem. People were randomly assigned to placebo or one of several retatrutide doses, then followed for 48 weeks (Jastreboff et al., NEJM 2023, PMID 37366315).

The headline result: at the highest 12 mg dose, average weight loss reached about 24.2% of starting body weight at 48 weeks. For a 250-pound person, that is roughly 60 pounds. Lower doses lost less in a clean dose-response pattern: about 8.7% at 1 mg, 17.3% at 4 mg, and 22.8% at 8 mg. The placebo group lost about 2%.

Two details matter for honesty here. First, this was a relatively small, mid-stage trial. Phase 2 trials are designed to find the right dose and check for early safety signals, not to be the final word. Second, weight loss had not flattened out at 48 weeks. The curve was still heading down when the study ended, which hints the real ceiling could be higher, but a hint is not a proven number.

Retatrutide: the Phase 3 TRIUMPH program

Retatrutide's large Phase 3 program is called TRIUMPH. The design of these registrational trials was laid out in a 2026 paper in Diabetes, Obesity and Metabolism (Giblin et al., DOM 2026, PMID 41090431). The program tests retatrutide not just for obesity but also for obstructive sleep apnea and knee osteoarthritis tied to excess weight.

On May 21, 2026, Eli Lilly released topline results from TRIUMPH-1, the first pivotal obesity trial. Per the company's announcement, average weight loss at 80 weeks was 19.0% at 4 mg, 25.9% at 9 mg, and 28.3% at 12 mg, versus about 2.2% for placebo (Eli Lilly press release, May 2026). A subgroup with higher starting BMI who stayed on the drug longer reached up to about 30% at 104 weeks.

Here is the critical caveat, and it is a big one. As of this writing, TRIUMPH-1 exists only as a company press release. It has not been published in a peer-reviewed journal, the full data tables are not public, and no outside experts have reviewed the methods. Press-release numbers from a drug's maker are the least independent form of evidence we have. They are usually accurate, but they are also chosen to look good. Treat the 28.3% figure as promising and probably real, not as settled science. That distinction is the whole point of reading critically.

Tirzepatide: the SURMOUNT trials

Tirzepatide's weight-loss evidence is much further along. The pivotal SURMOUNT-1 trial, also led by Jastreboff and published in NEJM in 2022, enrolled 2,539 adults with obesity or overweight without diabetes and followed them for 72 weeks (Jastreboff et al., NEJM 2022, PMID 35658024).

In that trial, average weight loss reached 22.5% at the 15 mg dose, versus 2.4% for placebo. About nine in ten people on tirzepatide lost at least 5% of their weight. Fat mass dropped roughly three times more than lean mass, which is a reassuring sign that most of the loss was fat, not muscle.

Tirzepatide also has SURMOUNT-2, a Phase 3 trial in people who have both obesity and type 2 diabetes, published in The Lancet in 2023 (Garvey et al., Lancet 2023, PMID 37385275). Weight loss is always smaller in people with diabetes, and tirzepatide delivered around 12 to 15% there. This matters for the retatrutide comparison, because the same pattern is expected: a drug that produces 28% in people without diabetes will produce noticeably less in people who have it.

Putting the numbers side by side

Drug and dose	Trial	Population	Duration	Average weight loss
Tirzepatide 15 mg	SURMOUNT-1	Obesity, no diabetes	72 weeks	~22.5%
Tirzepatide 15 mg	SURMOUNT-2	Obesity + diabetes	72 weeks	~12-15%
Retatrutide 12 mg	Phase 2 (NEJM)	Obesity/overweight	48 weeks	~24.2%
Retatrutide 12 mg	TRIUMPH-1 (topline only)	Obesity, no diabetes	80 weeks	~28.3%
Retatrutide 9 mg	TRIUMPH-1 (topline only)	Obesity, no diabetes	80 weeks	~25.9%

The simple read: at top doses, retatrutide appears to take off roughly 5 to 6 more percentage points of body weight than tirzepatide. On a 250-pound person, that is about 13 to 15 extra pounds. That is a meaningful gap. But notice that the strongest retatrutide number comes from an unpublished topline release, while the tirzepatide numbers come from fully published, peer-reviewed trials. You are not comparing two equally solid figures. You are comparing a proven number against a promising one.

A fair way to say it: retatrutide's published Phase 2 number (24.2%) edges out tirzepatide's published Phase 3 number (22.5%) by a small margin, and the unpublished Phase 3 topline (28.3%) widens that lead. The lead is probably real. The exact size is not yet locked in.

Why the third hormone might matter beyond weight

The glucagon receptor target is interesting for reasons other than the scale. In a Phase 2a trial published in Nature Medicine in 2024, retatrutide produced large reductions in liver fat in people with metabolic dysfunction-associated steatotic liver disease, sometimes called fatty liver (Sanyal et al., Nature Medicine 2024, PMID 38858523). Many participants saw their liver fat drop to near-normal levels. Glucagon's job of pushing the liver to burn fat is the likely reason.

Retatrutide has also been studied in type 2 diabetes. A Phase 2 trial published in The Lancet in 2023 showed strong blood-sugar improvements alongside weight loss (Rosenstock et al., Lancet 2023, PMID 37385280). This was important because there was a real worry: glucagon normally raises blood sugar. Activating its receptor could have made diabetes worse. It did not, likely because the GLP-1 and GIP components more than offset it. That is a genuine win for the design, but again, it is Phase 2 data, not a finished diabetes outcomes trial.

So retatrutide may end up being more than a stronger weight drug. It may have a specific edge in fatty liver. That story is early but real.

The energy-burn idea, examined honestly

The most repeated claim about retatrutide is that the glucagon target "boosts your metabolism." It is worth slowing down on that, because it is half true and half marketing.

What the science supports: glucagon receptor activation can raise resting energy expenditure and promote fat burning in the liver. In animal studies and early human work, triple agonists increased calories burned at rest in ways that pure GLP-1 drugs do not. That is a genuine mechanical difference, not a slogan.

What is less certain: how much of retatrutide's real-world weight loss actually comes from burning more versus eating less. Appetite suppression is still the heavy lifter for every drug in this class, retatrutide included. The energy-expenditure piece is likely a real bonus, but it is probably a supporting actor, not the star. Anyone promising that retatrutide lets you "eat what you want because it speeds up your metabolism" is overselling a mechanism that the data do not support at that level. The honest version: retatrutide makes you eat less, and on top of that, the glucagon component may help you burn a bit more and clear liver fat. Both effects point the same direction. Neither replaces the basic truth that the appetite effect drives most of the result.

Safety: where retatrutide carries more uncertainty

Both drugs share the side-effect profile of the whole GLP-1 family. Nausea, vomiting, diarrhea, and constipation are the most common complaints. These are usually mild to moderate, show up most during dose increases, and fade over time. Going slow with the dose is the main way to manage them.

Retatrutide's Phase 2 trial flagged a few signals worth knowing about:

Heart rate. Retatrutide raised resting heart rate in a dose-dependent way, peaking around week 24 and then easing. A modest bump in heart rate is common across this drug class, but the glucagon component may push it a little harder.
Blood sugar in people without diabetes. Because glucagon can raise blood sugar, the trials watched for it. In people without diabetes, some had small increases in glucose, though no dangerous hypoglycemia was reported. This is the side that needs the most long-term watching.
Skin sensitivity. A small share of people, around 7% versus 1% on placebo, reported cutaneous hyperesthesia, meaning unusual skin sensitivity. None were severe and none caused people to quit. This is a newer signal that is not seen as prominently with tirzepatide.

Tirzepatide's safety record is simply better understood. It has been used by millions of people, has years of post-approval monitoring, and its risks, including gallbladder problems and the class-wide concern about pancreatitis, are documented. Like all GLP-1 drugs, it carries a boxed warning about thyroid C-cell tumors based on rodent studies, and it is not for people with a personal or family history of medullary thyroid cancer or MEN 2.

The honest framing: retatrutide's known risks look manageable so far, but "so far" covers far fewer people and far less time than tirzepatide. New drugs sometimes reveal rare problems only after huge numbers of people use them. Retatrutide has not yet faced that test. If you want a side-effect deep dive on what is already established, see our GLP-1 side effects complete guide.

Muscle loss: the same caution applies to both

Any drug that causes fast, large weight loss takes some muscle along with the fat. The bigger the total loss, the bigger the absolute muscle loss, even when the fat-to-muscle ratio stays favorable. Because retatrutide may drive even more total loss than tirzepatide, the muscle question is, if anything, more pressing with it, not less.

The fixes are the same regardless of which drug you use: eat enough protein, lift weights or do resistance training, and lose weight at a sustainable pace rather than racing for the lowest number. None of that is drug-specific. Our guide on how to prevent muscle loss on GLP-1 medications covers the practical steps.

Who each drug is actually for

Tirzepatide is the choice you can act on today. It is FDA approved, available by prescription, covered by some insurance plans, and backed by the most complete evidence in this comparison. If you want a proven, available, strongly effective option right now, this is it. For most people deciding what to start in 2026, the real question is not retatrutide versus tirzepatide. It is tirzepatide versus semaglutide, both of which you can actually get.

Retatrutide is a future option, not a current one. As of mid-2026 it is not approved and not for sale through legitimate channels. You cannot get it from a normal pharmacy. Be very wary of any website selling "retatrutide" for weight loss right now. Research chemicals and gray-market peptides are unregulated, often mislabeled, sometimes contaminated, and dosing them yourself is genuinely dangerous. The clean version of retatrutide is the one being tested in trials under medical supervision, and that version is not something you can order.

If you are mapping out where the field is heading, retatrutide is the leading candidate to become the most powerful obesity drug yet. But "leading candidate" is not "approved treatment." For the broader picture of what is coming, see our overview of next-generation GLP-1 drugs in the pipeline. And for how today's two leaders stack up, our semaglutide vs tirzepatide head-to-head is the comparison that actually affects your choices this year.

What real-world results might look like

Trial numbers are averages, and averages hide a wide spread. In any of these studies, some people lose far more than the headline figure and some lose far less. A 28% average means plenty of people lost 35% or more, while others lost 15% or barely responded. The same is true for tirzepatide's 22.5%. So the realistic way to read these drugs is as a range, not a guarantee.

A few patterns hold across both drugs and are worth setting expectations around:

Your starting weight matters. People with higher BMI tend to lose a larger percentage and a much larger absolute amount. The retatrutide subgroup that hit 30% had higher starting BMI and stayed on longer.
Dose and patience matter. The biggest losses come at top doses reached gradually, and weight tends to keep falling for a year or more. People who quit early or stay on low doses see less.
Stopping reverses it. These are not cure-once drugs. Across the GLP-1 class, stopping the medication leads to significant weight regain over the following year unless habits have genuinely changed. Retatrutide is very unlikely to be different. Whatever you weigh on the drug is not where you stay if you come off it.

That last point is the one people most want to ignore. A stronger drug does not change the basic deal: the weight comes back when the medication stops, because the underlying biology of appetite and body-weight regulation does not stop when the injections do.

Cost and access reality

Tirzepatide is expensive without insurance, often running well over a thousand dollars a month at list price, though savings programs and self-pay vial options have brought the real cost down for many people. It is at least a known quantity with published prices, coupons, and coverage paths.

Retatrutide has no legitimate price because it is not for sale. When it is eventually approved, expect it to launch at premium pricing, the way every new branded obesity drug has. The idea that retatrutide will be cheap because it is "better" gets the economics backward. The most effective new drug in a category is usually the most expensive, at least at launch, and insurance coverage for obesity drugs is still inconsistent. So even after approval, access and cost will likely be the real barriers, not effectiveness. For most people, the practical near-term decision stays within the drugs you can actually fill at a pharmacy this year.

How strong is the evidence, really?

Let me grade this plainly, because the whole value of a comparison like this is honesty about certainty.

Claim	Evidence strength	Why
Tirzepatide produces ~22.5% weight loss at top dose	Strong	Large, published, peer-reviewed Phase 3 trial
Retatrutide produces ~24% at top dose (Phase 2)	Moderate	Published, but small and mid-stage
Retatrutide produces ~28% at top dose (Phase 3)	Weak so far	Company topline only, not yet published or peer-reviewed
Retatrutide beats tirzepatide on weight	Probable, not proven	Cross-trial comparison, no head-to-head study exists
Glucagon target adds energy burn and cuts liver fat	Moderate	Supported by Phase 2 liver-fat data, mechanism is plausible
Retatrutide long-term safety is acceptable	Unknown	Too few people, too little time

The single most important line in that table: there has never been a head-to-head trial of retatrutide against tirzepatide. Every comparison in this article, including the one in the title, is built by lining up separate trials with different participants, different lengths, and different methods. That is a reasonable way to estimate, and the gap is probably real. It is not the same as proof. A direct trial could shrink the gap, widen it, or surface trade-offs we cannot see from a distance.

Frequently Asked Questions

Is retatrutide better than tirzepatide for weight loss?

On the headline numbers, retatrutide appears to produce more weight loss, roughly 5 to 6 more percentage points at top doses. But there has never been a direct head-to-head trial, and retatrutide's strongest figure comes from an unpublished company release. So the most accurate answer is that retatrutide probably loses more weight, while tirzepatide has better-proven results. Both are true.

Can I get retatrutide right now in 2026?

Not through legitimate channels. Retatrutide is still in clinical trials and is not FDA approved, so no real pharmacy dispenses it. Products sold online as "retatrutide" are unregulated gray-market peptides with unknown purity and dosing, and using them is risky. The only safe access is through a supervised clinical trial.

Why does retatrutide have a glucagon target when tirzepatide does not?

The glucagon receptor adds a third effect: it can raise resting calorie burn and push the liver to burn its own fat. Tirzepatide's two targets mostly reduce appetite and improve blood sugar. Adding glucagon is meant to turn up energy expenditure on top of turning down food intake, which may explain the larger weight loss and the strong liver-fat results.

Does retatrutide have worse side effects than tirzepatide?

Both share the GLP-1 family's stomach side effects like nausea. Retatrutide's trials flagged a few extra signals, including modest heart-rate increases, small blood-sugar rises in people without diabetes, and some skin sensitivity. None looked severe in testing, but retatrutide has been studied in far fewer people for far less time, so its long-term safety is genuinely less certain than tirzepatide's.

Will retatrutide replace tirzepatide once it is approved?

Maybe for some people, but not automatically. If the Phase 3 data hold up in peer review, retatrutide could become the most effective option for those who need the largest weight loss or who have fatty liver. But tirzepatide will still be cheaper, more available, and better understood for years, and not everyone needs the maximum-strength drug.

This article is for general information only and is not medical advice. Talk to a licensed healthcare provider before starting, stopping, or changing any medication.